Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025.

The company will host a conference call with management to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the earnings call through the investor relations section of Pulmonx's website.

News Market Reaction – LUNG

-5.64%

-5.64% Session move

In the trading session that priced this news, LUNG declined 5.64%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX^™ Platform, and StratX^® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Laine Morgan
Gilmartin Group
investors@pulmonx.com

FAQ

When will Pulmonx (LUNG) release Q1 2025 earnings?

Pulmonx will release Q1 2025 earnings after market close on Wednesday, April 30, 2025.

How can investors access Pulmonx's Q1 2025 earnings call?

Investors can access the live and archived webcast through Pulmonx's investor relations website at investors.pulmonx.com. The call begins at 1:30 p.m. PT / 4:30 p.m. ET on April 30, 2025.

What time is Pulmonx (LUNG) Q1 2025 earnings conference call?

Pulmonx's Q1 2025 earnings conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on April 30, 2025.

Where can I find Pulmonx's (LUNG) Q1 2025 earnings webcast?

The earnings webcast will be available in the 'Investors' section of the Pulmonx website at investors.pulmonx.com.